Yarrow Bioscience (NASDAQ:YARW) Now Covered by Guggenheim

Equities research analysts at Guggenheim began coverage on shares of Yarrow Bioscience (NASDAQ:YARW) in a report issued on Friday, Marketbeat Ratings reports. The firm set a “buy” rating and a $60.00 price target on the stock. Guggenheim‘s target price would suggest a potential upside of 341.18% from the stock’s current price.

Other analysts have also recently issued reports about the stock. BTIG Research initiated coverage on shares of Yarrow Bioscience in a research note on Monday, August 3rd. They issued a “buy” rating and a $58.00 target price for the company. TD Cowen assumed coverage on shares of Yarrow Bioscience in a research note on Tuesday, July 28th. They issued a “buy” rating for the company. Finally, Wall Street Zen upgraded shares of Yarrow Bioscience to a “hold” rating in a research note on Saturday, August 22nd. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $59.00.

Yarrow Bioscience Trading Down 8.8%

Yarrow Bioscience stock opened at $13.60 on Friday. The stock has a 50 day moving average price of $23.78. Yarrow Bioscience has a fifty-two week low of $12.39 and a fifty-two week high of $46.95.

Yarrow Bioscience (NASDAQ:YARW) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($3.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($3.33). The business had revenue of $0.10 million for the quarter, compared to analysts’ expectations of $0.20 million. Yarrow Bioscience had a negative net margin of 4,726.21% and a negative return on equity of 84.40%.

Institutional Investors Weigh In On Yarrow Bioscience

Hedge funds have recently modified their holdings of the business. Two Sigma Securities LLC acquired a new stake in shares of Yarrow Bioscience in the second quarter worth $26,000. BlackRock Inc. bought a new position in Yarrow Bioscience during the second quarter worth $29,000. GSA Capital Partners LLP bought a new position in Yarrow Bioscience during the second quarter worth $47,000. Rangeley Capital LLC raised its stake in Yarrow Bioscience by 18.1% during the 1st quarter. Rangeley Capital LLC now owns 118,064 shares of the company’s stock valued at $71,000 after purchasing an additional 18,064 shares during the last quarter. Finally, Susquehanna International Group LLP acquired a new position in Yarrow Bioscience during the 2nd quarter valued at $77,000. 83.78% of the stock is owned by institutional investors.

Yarrow Bioscience Company Profile

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.